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ABSTRACT
Background: The detection of BRAFV600 mutations in patients with metastatic 
melanoma is important because of the availability of BRAF inhibitor therapy. However, 
the clinical relevance of the frequency of BRAFV600 mutant alleles is unclear.
Patients and Methods: Allele frequencies of BRAFV600 mutations were analyzed 
byultra-deepnext-generation sequencing in formalin-fixed, paraffin-embedded 
melanoma tissue (75 primary melanomas and 88 matched metastases). In a second 
study, pretreatment specimens from 76 patients who received BRAF inhibitors were 
retrospectively analyzed, and BRAFV600 allele frequencies were correlated with 
therapeutic results.
Results: Thirty-five patients had concordantly BRAF-positive and 36 (48%) 
patients had concordantly BRAF-negative primary melanomas and matched 
metastases, and four patients had discordant samples with low allele frequencies 
(3.4–5.2%). Twenty-six of 35 patients with concordant samples had BRAFV600E 
mutations, three of whom had additional mutations (V600K in two patients and 
V600R in one) and nine patients had exclusively non-V600E mutations (V600K in eight 
patients and V600E -c.1799_1800TG > AA- in one patient). The frequency of mutated 
BRAFV600 alleles was similar in the primary melanoma and matched metastasis 
in 27/35 patients, but differed by >3-fold in 8/35 of samples. BRAFV600E allele 
frequencies in pretreatment tumor specimens were not significantly correlated with 
treatment outcomes in 76 patients with metastatic melanoma who were treated with 
BRAF inhibitors.
Conclusions: BRAFV600 mutation status and allele frequency is consistent in 
the majority of primary melanomas and matched metastases. A small subgroup of 
patients has double mutations. BRAFV600 allele frequencies are not correlated with 
the response to BRAF inhibitors.
INTRODUCTION
In patients with BRAFV600E-positive melanoma 
enrolled in large randomized phase III studies, treatment 
with BRAF kinase inhibitors such as vemurafenib and 
dabrafenib resulted in response rates of over 50–60% and 
progression-free survival (PFS) of 6–7 months. Among 
nonresponders in these trials, the majority had an initial 
period of disease stabilization, and only a minority had 
primary resistance to BRAF inhibitor therapy [1, 2].
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Precise selection of patients is crucial for optimal 
use of BRAF inhibitor therapy. BRAF mutations may be 
detected in archived formalin-fixed, paraffin-embedded 
(FFPE) melanoma tissue; however, it is currently unclear 
whether primary tumors, consecutive metastases, or 
both should be preferentially analyzed because of the 
possibility of intertumor heterogeneity [3]. It is also 
unclear whether the allele frequency of BRAFV600E 
mutations is correlated with response to BRAF kinase 
inhibitors. Thus in the first study population, we evaluated 
BRAFV600 mutations and allele frequencies in FFPE 
melanoma specimens using ultra-deep next-generation 
sequencing (NGS) and compared the results in primary 
melanomas and matched metastases. In a second study 
population we used NGS to evaluate BRAFV600 
mutations in pretreatment melanoma specimens from 
76 patients with metastatic melanoma who subsequently 
received BRAF inhibitors, and examined correlations 
between BRAFV600 allele frequencies, PFS, overall 
survival (OS), and objective response.
RESULTS
BRAFV600 mutational status was determined by 
ultra-deep NGS in 163 FFPE tissue samples obtained 
from 75 patients (Table 1 and 2). The primary melanoma 
and consecutive metastases from one, two, and three 
Table 1: Frequencies (%) of BRAFV600-mutated alleles detected by next-generation sequencing 
(NGS)
Patient number Melanoma 
sample
NGS result V600E (%) V600K (%) V600R (%) V600E2 (%)
1 pm V600E 18,3 0 0 0
ln V600E 3,7 0 0 0
2 pm V600E 24,4 0 0 0
ln V600E 18,7 0 0 0
sc V600E 24,6 0 0 0
visceral V600E 25,6 0 0 0
3 pm V600E 45,1 0 0 0
sc V600E 17,7 0 0 0
4 pm V600E 78,5 0 0 0
sc V600E 86,5 0 0 0
5 pm V600E 38,5 0 0 0
Ln V600E 45,3 0 0 0
6 pm V600E 40,8 0 0 0
sc V600E 33,2 0 0 0
7 pm V600E 61,3 0 0 0
sc V600E 50,9 0,1 0 0
8 pm V600E 9,4 0 0 0
sc V600E 7,4 0 0 0
9 pm V600E 24,5 0 0 0
sc V600E 69 0 0 0
10 pm V600E 10,6 0 0 1,8
ln V600E 8,1 0 0 0
11 pm V600E 31,9 0 0 0
sc V600E 20,1 0 0 0
ln V600E 17,3 0 0 0
(Continued ) 
Oncotarget3www.impactjournals.com/oncotarget
Patient number Melanoma 
sample
NGS result V600E (%) V600K (%) V600R (%) V600E2 (%)
12 pm V600E 23,9 0 0 0
sc V600E 47,2 0 0 0
13 pm V600E 5 0,1 0 0
ln V600E 16 0 0 0
14 pm V600E 29 0 0 0
sc V600E 36,2 0 0 0
ln V600E 40,7 0,1 0 0
15 pm V600E 21 0 0 0
ln V600E 10,9 0 0 0
16 pm V600E 51,2 0 0 0
sc V600E 24,2 0 0 0
17 pm V600E 26,9 0 0 0
sc V600E 46,6 0 0 0
ln V600E 58 0 0 0
18 pm V600E 23,4 0 0 0
sc V600E 54,3 0 0 0
19 pm V600E 44,2 0 0 0
ln V600E 14,6 0 0 0
sc V600E 28,3 0 0 0
20 pm V600E 22,4 0 0 0
sc V600E 7,1 0 0 0
21 pm V600E 7 0 0 0
sc V600E 49,5 0,2 0 0
22 pm V600E 31,9 0 0 0
ln V600E 34,7 0,2 0 0
23 pm V600E 28,1 0,1 0 0
sc V600E 24,4 0 0 0
24 pm V600E 12,7 0 0 0
ln V600E 92,2 0 0 0
25 pm V600E 23,6 0 0 0
brain V600E 54,2 0 0 0
26 pm V600E 5,6 0 1,4 0
ln V600E+R 20,8 0 11,4 0
27 pm V600K 0,1 34 0 0
sc V600K 0 23,4 0 0
28 pm V600K 0 66,2 0,2 0
ln V600K 0 9,6 0,1 0
(Continued ) 
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locations were available for 63, 11, and one patient, 
respectively. In addition to the 75 primary melanoma 
samples, the analysis included 49 skin metastases, 36 
lymph node metastases, two visceral metastases, and one 
brain metastasis.
Among the 163 tissue samples evaluated, 81 
(50%) specimens were BRAFV600-negative, 79 
(48%) specimens had a single BRAFV600 mutation. 
61 patients had BRAFV600E (c.1799T > A), 16 
had BRAFV600K (c.1798_1799GT > AA) and two 
patients had BRAFV600E (c.1799_1800TG > AA), and 
three (2%) specimens had two different BRAFV600 
mutations; two had BRAFV600E (c.1799T > A) 
and BRAFV600K (c.1798_1799GT > AA) and one 
had BRAFV600E(c.1799T > A) and BRAFV600R 
(c.1798_1799GT > AT, Table 1).
Evaluation of BRAF status in primary 
melanomas and matched metastases by NGS
Consistent mutation patterns in primary tumors and 
matched metastatic lesions were observed in 71 of 75 
(95%) patients. A total of 35 patients had concordantly 
BRAF-positive and 36 (48%) patients had concordantly 
BRAF-negative primary melanomas and matched 
metastases The four (5%) remaining patients each had one 
BRAFV600-positive and one BRAFV600-negative sample. 
In three of these four patients, the primary melanoma was 
Patient number Melanoma 
sample
NGS result V600E (%) V600K (%) V600R (%) V600E2 (%)
29 pm V600K 0,1 44,5 0 0
ln V600K 0 12,7 0 0
30 pm V600K 0 46,5 0 0
ln V600K 0 47,8 0 0
sc V600K 0,2 50,7 0 0
31 pm V600K 0,5 34,4 0 0
ln V600K 0 83,7 0 0
32 pm V600K 0 32,8 0 0
sc V600K+E 13,1 19,1 0 0
33 pm V600K 0 13,2 0 0
sc V600K+E 5,2 14,6 0 0
34 pm V600E2 0 0 0 30,2
sc V600E2 0,1 0 0 72,9
35 pm V600K 2 17,7 0 0
sc V600K 0 45,5 0 0
sc V600K 0,1 43,4 0 0
36 pm V600E 5,2 0 0 0
sc wild type 0,1 0 0 0
37 pm V600E 4,5 0 0 0
sc wild type 0 0 0 0
38 pm wild type 0 0 0 0
sc V600E 3,4 0 0,2 0
39 pm V600E 5 0 0 0
sc wild type 0 0 0 0
sc wild type 0,8 0 0 0
Three patients (26, 32, and 33) had double (BRAFV600E and non-BRAFV600E) mutations. NGS allele frequencies >3% 
were considered to be positive (pm = primary melanoma, ln = lymph node metastasis, sc = subcutaneous.
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BRAFV600-positive, and in the one remaining patient 
the metastatic tissue alone was BRAFV600-positive 
(Table 1). Of note, the BRAFV600 allele frequencies were 
low (3.4–5.2%) in the positive samples from these four 
individuals (Table 1).
BRAFV600E (c.1799T > A) mutations and rare 
mutations by NGS
Among the 35 patients with concordantly BRAF-
positive samples, 26 patients had a BRAFV600E 
(c.1799T > A) mutation in both the primary melanoma 
and consecutive metastases, eight patients had BRAF 
V600K (c.1798_1799GT > AA) mutations (eight primary 
melanomas, four lymph node metastases, and four 
skin metastases), and one patient had a BRAFV600E 
(c.1799_1800TG > AA) mutation (in the primary melanoma 
and matched skin metastasis) (Table 1). Three metastatic 
specimens from these 35 patients (two skin metastases 
and one lymph node metastasis) showed BRAFV600K 
(c.1798_1799GT > AA, n = 2) or BRAFV600R 
(c.1798_1799GT > AT; n = 1) mutations with an allele 
frequency >3%, in addition to BRAFV600E (c.1799T > A).
Frequencies of mutated BRAFV600 alleles in 
primary melanomas and matched metastases  
by NGS
The median percentage of mutated alleles was 28% 
in primary melanomas and 26% in consecutive metastases 
(Figure 1). The mutant allele frequency was higher in the 
primary melanoma than in the metastases in 16 patients, 
and higher in the metastases than the primary melanoma in 
19 patients (Table 1, Figure 1). In 27 of 35 (77%) patients 
with BRAFV600 mutations, the percentage of mutated 
alleles in the primary melanoma and metastases differed 
by <3-fold. In the eight patients in whom the percentage of 
mutated alleles in the primary melanoma and metastases 
differed by >3-fold, the frequencies of mutated alleles 
was higher in the primary melanoma in four patients and 
higher in the metastases in four patients. The differences in 
allele frequencies between primary and metastatic tissue in 
six of these eight patients could be attributed to differences 
in tumor cell content in the various tissues.
Allele frequencies of patients treated with BRAF 
inhibitors and their impact on therapy outcome
Pretreatment samples from 76 patients with 
BRAFV600E-positive metastatic melanoma who were treated 
with the BRAF inhibitors vemurafenib (n = 67) or dabrafenib 
(n = 9) were retrospectively analyzed by NGS. The baseline 
characteristics and response to therapy after a mean follow-
up of 11.4 months are summarized in Table 3. The available 
samples included nine primary melanomas, 29 lymph node 
metastases, 28 cutaneous or subcutaneous metastases, eight 
visceral metastases, and two brain metastases. As shown in 
Table 3, BRAFV600E (c.1799T > A) allele frequencies in 
pretreatment melanoma tissue were ≤5% in two patients, >5–
10% in four patients, >10–15% in three patients, >15–20% in 
11 patients, > 20–25% in 6 patients, >25–50% in 33 patients, 
and >50% in 17 patients.
Allele frequencies were not significantly 
correlated with either PFS or OS in Kaplan-Meier 
Table 2: Clinical characterization of 75 patients; 75 primary melanomas of these patients and 88 
matched metastases were analyzed by ultra-deep next generation sequencing to compare BRAFV600 
status and BRAFV600 allele frequencies of primary melanomas and matched metastases
Clinical parameters
Total patients N 75 (100%)
Gender Male 46 (61%)
Female 29 (39%)




Tissue tested Primary melanoma 75





analyses in which different cut-offs were used (≤15%, 
≤18%, ≤20%, and ≤25%). Comparisons of PFS and OS 
in patients with allele frequencies ≤18 and >18% are 
shown in Figure 2 (p = 0.374 for PFS and p = 0.898 
for OS). Odds Ratio was calculated to determine the 
magnitude of differences that can be detected with this 
relatively small cohort (Table 4).
The response to therapy (complete response [CR] 
and partial response [PR] versus stable disease [SD], mixed 
response [MR], and progressive disease [PD]) was not 
significantly correlated with allele frequencies in univariate 
analyses in which different cutoffs were used (15%, 18%, 
20%, and 25%). A total of 9, 15, 20, and 26 patients had 
BRAFV600E allele frequencies ≤15%, ≤18%, ≤20%, and 
≤25%, respectively. Response rates (CR and PR) in these 
categories were as follows: BRAFV600E allele frequency 
≤15% versus >15% (44% and 61%, p = 0.473); ≤18% 
versus >18% (40% and 64%, p = 0.142); ≤20% versus 
>20% (45% and 64%, p = 0.185); and ≤25% versus >25% 
(50% and 64%, p = 0.326).
DISCUSSION
Since the discovery of BRAF mutations 
in melanoma in 2002 [4], advances in molecular 
characterization of the disease have led to the development 
of specific BRAF inhibitors that are now available for the 
treatment of patients with metastatic melanoma. In the first 
part of this study, we used ultra-deep NGS to assess the 
BRAFV600 mutation status of primary melanomas and 
matched metastases and their influence on the outcome of 
BRAF inhibitor therapy.
For the first time, we showed that type and 
frequency of BRAFV600 mutations are consistent in the 
primary melanoma and matched metastases in the majority 
of patients. In most patients with discordant BRAFV600 
status, in which one tissue sample was positive and 
one sample negative, this could be explained by low 
allele frequencies where the allele frequency was close 
to the threshold of detection in the positive sample but 
below the threshold of detection in the negative sample. 
Differences in allele frequencies could also be explained 
by differences in tumor cell content in the specimens. 
These results suggest that, in the majority of melanoma 
cases, the BRAF mutation status of the primary tumor is 
retained in metastases, and that primary and/or metastatic 
tissue can be used for routine mutational analysis provided 
that sufficient tumor cell content is available.
Five recently published studies have analyzed 
the BRAF mutation status of melanoma samples with 
different molecular methods (Table 5). Consistent 
with our observations, these analyses also found the 
mutational status of primary tumor and metastatic tissue 
to be concordant in the majority of cases. Intrapatient 
homogeneity of BRAF mutations has also been reported 
in all patients (n = 64) included in a recent study that used 
immunohistochemical methods for detection of BRAF 
mutants [5].
Our findings suggest that melanomas can be 
heterogeneous with regard to BRAFV600 mutations. The 
allele frequency was below 50%, which would be the 
Figure 1: Allele frequencies (%) of BRAFV600 mutations in primary melanomas (pm) and matched metastases (mm) 
in 35 patients with metastatic melanoma. 
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Table 3: Characterization of 76 patients with BRAFV600E mutations who were treated with BRAF 
inhibitors for metastatic melanoma
Clinical parameters
Total patients N 76 (100%)
Gender Male 41 (54%)
Female 35 (46%)




Tissue tested Primary melanoma 9 (12%)
Lymph node metastases 29 (38%)
Cutaneous metastases 28 (37%)
Visceral metastases 8 (10%)
Brain metastases 2 (3%)
Allele frequencies Mean 31.9










BRAF inhibitor Vemurafenib 67 (88%)
Dabrafenib 9 (12%)
Prior therapies for metastatic melanoma No 44 (57%)
1 prior therapy 12 (16%)
2 prior therapies 14 (19%)
3 prior therapies 3 (4%)
≥4 prior therapies 3 (4%)
Response to treatment







expected result if cells show a consistent heterozygous 
mutation. For example, patient number 2 showed allele 
frequencies that ranged from 18.7% to 25.6% in the 
primary tumor and three metastatic samples (Table 1). 
The results of a study that used a BRAFV600E-specific 
antibody and showed heterogeneous staining in 13 of 58 
(22%) melanoma samples provides further evidence of 
heterogeneity of BRAFV600 mutations [6]. Moreover, a 
further study that used single cell suspensions to assess 
BRAF mutations found 9 of 10 primary melanomas and 0 
of 3 metastases to be heterogeneous [7].
Despite these data that suggest BRAFV600 
mutations are heterogeneous, the clinical response to 
BRAF inhibitors is homogenous [1, 2] and suggests that 
the BRAFV600 mutation is relevant in the majority of 
melanoma cells.
Approximately 10% of patients with BRAF 
V600 mutations had double mutations, comprised 
of the BRAFV600E and an additional rare mutation. 
This phenomenon has not been reported previously 
and demonstrates the ability of NGS to detect different 
mutations that are difficult or impossible to detect 
with techniques used in other studies, such as Sanger 
sequencing, pyrosequencing or melting curve analyses 
[3, 8–11]. This phenomenon may also be the result of 
intratumor heterogeneity.
Time to progression (months) Mean 5.5
Median 7.1
Minimum–maximum 0.5–26.1
Progression No 15 (20%)
Yes 61 (80%)
Follow-up
Death No 31 (41%)
Yes, due to melanoma 41 (54%)
Yes, other cause 4 (5%)
Follow-up (months) Mean 11.4
Median 9.7
Minimum–maximum 0.8–27.8
(sc = subcutaneous, CR = complete response, MR = mixed response, PD = progressive disease, PR = partial response,  
SD = stable disease).
Figure 2: Progression-free survival (PFS) and overall survival (OS) of patients with BRAFV600 allele frequencies  
≤18% and >18%. 
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Allele frequencies had no impact on PFS, OS, 
and objective response rates in the 76 patients with 
BRAFV600E-positive metastatic melanoma treated 
with BRAF inhibitors. Although the usual precautions 
regarding retrospective analyses apply, the median PFS of 
7.1 months and the response rate of 60% are very close 
to the results of the phase III studies [1, 2], supporting 
the validity of our findings. These results are also in 
line with the recently published observation of Wilmott 
et al. that the intensity and distribution of BRAFV600E 
immunohistochemical staining is not correlated with 
clinical outcomes [6].
The observation that patients with allele 
frequencies <18% and ≥18% have similar PFS and OS is 
clinically relevant, because an allele frequency of 18% 
is around the detection limit of Sanger sequencing [12], 
which is commonly used in routine clinical practice. 
Thus, in the case of a negative Sanger sequencing result, 
our data suggest that retesting with a more sensitive 
assay may be worthwhile to detect alleles that may be 
present at lower frequencies.
In conclusion, we show here that BRAFV600 
mutation status and allele frequency are consistent 
in the majority of primary melanomas and matched 
metastases, that a subgroup of patients has double 
mutations, and that the allele frequency of melanoma 
tissue is not correlated with treatment response in our 
patient cohort.
Table 4: Required 95% confidence interval limits for statistical significance in response analysis
Parameters Cut-offs
15% 18% 20% 25%
Proportion π1 15% 25% 28% 31%
Proportion π2 61% 64% 64% 64%
Odds ratio1 8.86 5.33 4.57 3.96
Distance –2 1.89 1.28 1.12 1.01
Lower limit3 1.33 1.48 1.49 1.44
Upper limit3 58.93 19.19 13.99 10.89
Note: π1: proportion of responders with BRAFV600E allele frequency ≤ cut-off; π2: proportion of responders with 
BRAFV600E allele frequency > cut-off.
1This is the minimum required effect size estimated for power equal to 80% (proportion of responders with BRAFV600E 
allele frequency > cut-off against proportion of responders with BRAFV600E allele frequency ≤ cut-off).
2Distance refers to the difference between the logarithm of odds ratio and its lower limit.
3Results are presented in the exponential (original) scale.
Table 5: Evaluation of BRAFV600 mutations in primary melanomas and matched metastases by 
different molecular detection methods
Detection method Tumor cell content (%) Concordance rate, n/N (%) Ref.
NGS >30 71/75(95) This study
HRM + direct sequencing 
(Sanger) >10 84/88(95) (12)
MS-PCR + direct sequencing 
(Sanger) <33 to >67 10/18 (56) (3)
Pyrosequencing >75 43/53(81) (14)
Direct sequencing (Sanger) NS 21/24(87) (13)
Direct sequencing (Sanger) ≥80 87/102(85) (16)
(HRM = high-resolution melting curve analysis, MS-PCR = mutagenically separated polymerase chain reaction, NGS = 




In the first study population we retrospectively 
analyzed melanoma samples from patients with metastatic 
melanoma who were treated at the Skin Cancer Center 
Hannover, Germany, between 1995 and 2011. Patients 
were selected for this study on the basis of availability 
of primary melanoma tissue and tissue from at least one 
matched metastasis.
In a second different study population, BRAFV600 
allele frequencies were determined by NGS in 
pretreatment melanoma tissue specimens from metastatic 
melanoma patients who were treated with BRAF 
inhibitors at three German skin cancer centers (Munich, 
Erfurt and Hannover). Patients had been treated with 
standard dosages of vemurafenib (960 mg b.i.d.) in a 
phase III clinical trial [13] or expanded access program, 
or dabrafenib (150 mg b.i.d.) in phase III clinical trials 
[14]. Only patients with BRAFV600E mutations and 
with pretreatment FFPE tumor specimens available for 
NGS analysis were included. Patients with non-V600E 
mutations and patients with double mutations were 
excluded.
Response to therapy in the clinical trials was 
assessed with computed tomography every 8–12 weeks, as 
required by the protocols [13, 14]. Tumor responses were 
determined according to Response Evaluation Criteria In 
Solid Tumors (RECIST) version 1.1 [15].
Histopathology, macrodissection,  
DNA extraction
One slide at the beginning of each serial section was 
stained with hematoxylin-eosin and histopathologically 
examined to determine the tumor cell content. Only 
samples with a tumor cell content of at least 30% were 
included in this study. The area of interest was circled on 
the stained slide and macrodissection was performed on 
the corresponding unstained slides using a scalpel. DNA 
was extracted using the cobas® DNA Sample Preparation 
Kit (Roche, Grenzach-Wyhlen, Germany).
Ultra-deep NGS
Isolated DNA (350–976 ng) from all FFPE 
specimens was subjected to analyses by NGS using a 
Roche GS Junior System to detect BRAFV600 mutations 
on exon 15. The NGS procedure was done according 
to the manufacturer’s specifications [16]. Amplicon 
processing, library preparation and emulsion PCR were 
done according to the manufacturer’s directions for the 
GS Junior Titanium Series (Roche). Around 500,000 
enriched beads were loaded on a 454 Junior Sequencer 
(Roche, Basel, Switzerland). Demultiplexing and variant 
calling was done with the Amplicon Variant Analyzer v2.7 
software from Roche. The average sequencing coverage of 
BRAF was >5000. The presence of a BRAFV600 mutation 
was defined as the presence of a non-reference base in a 
minimum of 3% of reads.
Approval by ethics committee
The collection of clinical and follow-up data, 
performance of mutational analyses, and correlation with 
clinical data was approved by the Ethics Committee of 
Hannover Medical School (vote 1849-2013).
Statistical analyses
Associations between BRAFV600E allele 
frequencies and clinical outcomes were tested by log-
rank test (Kaplan-Meier analyses) using different allele 
frequencies as cutoffs (15%, 18%, 20%, and 25%). 
Qualitative comparisons of objective response to therapy 
with BRAF inhibitors were performed using RECIST 
1.1 criteria. In these comparisons, responders were 
defined as having either a CR or PR and nonresponders 
were defined as having SD, an MR, or PD. Analyses of 
responses to therapy (response versus nonresponse) and 
allele frequencies were performed by using a two-tailed 
Fisher’s exact test. Statistical significance was defined as 
an alpha level <0.05. SPSS 19.0 (SPSS Inc; Chicago, IL, 
USA) was used for Kaplan-Meier tests, Fisher’s exact test 
and calculation of Odds ratio (OR).
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